Oral anticoagulants compared with dual antiplatelet therapy after atrial appendage closure: a systematic review
DOI:
https://doi.org/10.36557/2674-8169.2024v6n8p3917-3926Keywords:
Oral Anticoagulant, Dual Antiplatelet Therapy, atial Appendage OcclusionAbstract
This article aims to evaluate the ideal anticoagulation therapy for patients undergoing atrial appendage occlusion. The search engines PubMed and Embase were used to select articles, using the keywords “Oral anticoagulation, dual antiplatelet therapy, atrial appendage occlusion”. It is concluded that patients undergoing left atrial appendage occlusion should use antiplatelet therapy, however the choice should be individualized, since some patients do not have an indication for dual therapy.
Downloads
References
AFZAL, S. et al. Optimal antithrombotic regimen in left atrial appendage occlusion: The Gordian knot? Pharmacology, v. 108, n. 2, p. 199–203, 2023.
BRIOSA E GALA, A. et al. Short dual antiplatelet strategy following left atrial appendage closure with Watchman and Watchman FLX: 1-year outcomes. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, v. 23, n. Supplement_3, 2021.
CARVALHO, P. E. P. et al. Network meta-analysis of initial antithrombotic regimens after left atrial appendage occlusion. Journal of the American College of Cardiology, v. 82, n. 18, p. 1765–1773, 2023.
CEPAS-GUILLEN, P. L. et al. Low dose of direct oral anticoagulants after left atrial appendage occlusion. Journal of cardiovascular development and disease, v. 8, n. 11, p. 142, 2021.
FREIXA, X. et al. Low-Dose Direct Oral Anticoagulation vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion: The ADALA randomized clinical trial: The ADALA randomized clinical trial. JAMA cardiology, 2024.
JACKSON, L. R., 2nd; JACKSON, K. P.; THOMAS, K. L. Percutaneous left atrial appendage occlusion: A review of current devices, clinical evidence, patient selection, and post procedural antithrombotic management. Progress in cardiovascular diseases, v. 66, p. 92–100, 2021.
MAZZONE, P. et al. Role of different antithrombotic regimens after percutaneous left atrial appendage occlusion: A large single center experience. Journal of clinical medicine, v. 10, n. 9, p. 1959, 2021.
MHANNA, M. et al. Single versus dual antiplatelet therapy following Left atrial appendage occlusion in patients with high bleeding risk. Current problems in cardiology, v. 47, n. 9, p. 101269, 2022.
PIERPOLINE, M. et al. Impact of valvular heart disease, anticoagulation, and left atrial appendage occlusion devices: A novel approach. Journal of the American College of Cardiology, v. 73, n. 9, p. 525, 2019.
SANTOS, V. V. et al. ACIDENTE VASCULAR CEREBRAL ISQUÊMICO AGUDO. Em: Guia de Emergência em uma página. [s.l.] Even3 Publicações, 2024.
TJOE, B. et al. Use of direct oral anticoagulation therapy following implantation of the watchman left atrial appendage occlusion device. Structural heart, v. 5, n. 3, p. 295–301, 2021.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Mari Edeline veras Dourado, Raquel Araújo Nogueira, Sebastián Alonso Hernández Camacho, Isadora Rodrigues Almeida, Anna Carolina de Araújo, Gabriela Santos Vieira Marques , Ana Beatriz Aguiar Cardoso, Julia Favin, Ayla Tarzan Lima Modesto, Brenda Ferreira da Silva, Gabriela Paz Mendes de Lima, David Garcia de Alcaraz Conti, Júlia Zanin Caldas, Ana Vitória Dias de Sousa, Renata Boccamino Buzzi Cotrim, Isabella Bueno Pereira da Rocha, Afonso Neiva Cavalcante, Kalline Esdra Lima Queiroz, Bruna Ribeiro de Almeida Freitas
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors are copyright holders under a CCBY 4.0 license.
